| Year |
Keynote Speaker |
School |
Title / Topic |
| 2005 |
Doriano Fabbro, Ph.D. |
Novartis Institutes for Biomedical Research |
20 years of kinase inhibitors: have we achieved a significant therapeutic progress? |
| 2004 |
Steven T. DeKosky, M.D. |
University of Pittsburgh Medical Center |
Intervention in Alzheimer's Disease: A New Age |
| 2003 |
Jordan J.N. Tang, Ph.D. |
Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center |
Probing Beta-Secretase for Keys to Alzheimer's Disease |
| 2002 |
Carolyn Bertozzi, Ph.D. |
University of California at Berkeley |
Therapeutic Opportunities in Sulfation Pathways |
| 2001 |
Lloyd A. Greene, Ph.D. |
Columbia University |
Neuronal Cell Death and its Abatement: Strategies and Counterstrategies |
| 2000 |
Christopher T. Walsh, Ph.D. |
Harvard Medical School |
Biogenesis of Non-Ribosomal Peptide Antibiotics: Assembly Line Enzymology |
| 1999 |
Richard A. Lerner, Ph.D. |
Scripps Institute |
Catalytic Antibodies: Using Reactive Immunization to Produce Antibody Aldolases of Remarkable Efficiency |
| 1998 |
Bruce S. McEwen, Ph.D. |
Rockefeller University |
Sex, Stress and the Hippocampus |
| 1997 |
Allen D. Roses, M.D. |
Glaxo Wellcome (GSK) |
Apolipoprotein E and Alzheimer's Disease |
| 1996 |
F. Raymond Salemme |
3-Dimensional Pharmaceuticals |
The Future of Drug Discovery: Integration of Computer-Directed Combinatorial Chemistry and Structure-Based Drug Design |
